Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:45 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21461
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 25–36 of 21,461 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
561
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 431 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Recruiting Phase 1 Interventional

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

NCT06959706
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TGW101
Drug
Lead sponsor
Tagworks Pharmaceuticals BV
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Philadelphia, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

NCT06944522
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
bemdaneprocel, Sham surgery
Biological · Procedure
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
45 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
34
States / cities
Scottsdale, Arizona • Sun City, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424
View directory record Official record
Conditions
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
673
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Recruiting Phase 3 Interventional

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
92
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229
View directory record Official record
Conditions
Carcinoma
Interventions
Osimertinib, Savolitinib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Not yet recruiting No phase listed Observational

Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity

NCT07911046
View directory record Official record
Conditions
Pediatric Obesity, Obesity
Interventions
Semaglutide
Drug
Lead sponsor
Erin Mauney
Other
Eligibility
12 Years to 15 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Recruiting Phase 3 Interventional

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression
Interventions
CYB003, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

NCT04647253
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
AGENT DCB, PTCA balloon catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Recruiting Not applicable Interventional

Effect of Support for Low-Income Mothers of Preterm Infants

NCT06362798
View directory record Official record
Conditions
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less)
Interventions
Financial Transfers
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Terminated Phase 2 Interventional

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

NCT05579639
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
Xylitol, Placebo
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 25 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST
Recruiting Phase 3 Interventional

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

NCT07061977
View directory record Official record
Conditions
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
344
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 265 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 9:45 PM EST